Repair Biotechnologies, Inc.
Syracuse, NY · Founded 2018 · CIK 0001750699 · Biotech · Private
Cholesterol Degrading Platform (CDP) therapy enabling human cells to degrade cholesterol
repairbiotechnologies.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $25M
- 8 Form D · Nov 2025
- 11 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 12
- 1 granted · 11 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $450,000 | |
| Private capital raised | Form D · SEC | $75,000 | |
| Private capital raised | Form D · SEC | $1,270,000 | |
| Private capital raised | Form D · SEC | $2,855,000 | |
| Private capital raised | Form D · SEC | $200,000 | |
| Private capital raised | Form D · SEC | $8,389,479 | |
| Private capital raised | Form D · SEC | $6,166,000 | |
| Private capital raised | Form D · SEC | $5,258,906 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1616 | Generate Biomedicines | — | — |
| 1617 | Provizigen LLC | — | — |
| 1618 | ALZHEON, INC. | — | $134M |
| 1619 | Repair Biotechnologies, Inc. | — | $25M |
| 1620 | REELIN THERAPEUTICS, INC. | — | — |
| 1621 | DASFANH BIOSCIENCES, LLC | — | — |
| 1622 | Verdiva Bio | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Guilherme Cherman Perdigao de OliveiraDirector · Executive Officer
- Guilherme Cherman Perdig?o de OliveiraDirector
- Anthony ChowDirector
- Kelsey MoodyDirector
- Reason N/ADirector · Executive Officer
- Guilherme OliveiraDirector
Patents
- Targeted Expression Of Microbial Cholesterol Catalysis Genes Reduces Excess Lipidgranted
- Hepatocellular Carcinoma Treatments, Prophylactic Therapies, And Compositions For Use Therewithapplication
- Enhancing Mitochondrial-based Flow And Catabolism Of Cholesterolapplication
- Enhancing Mitochondrial-based Flow And Catabolism Of Cholesterolapplication
- Targeted Expression Of Microbial Cholesterol Catalysis Genes Reduces Excess Lipidapplication
- Hepatocellular Carcinoma Treatments, Prophylactic Therapies, And Compositions For Use Therewithapplication
- Enhancing Mitochondrial-based Flow And Catabolism Of Cholesterolapplication
- Targeted Expression Of Microbial Cholesterol Catalysis Genes Reduces Excess Lipidapplication
- Atherosclerotic Plaque Reduction Treatments And Compositionsapplication
- Targetted Expression Of Microbial Cholesterol Catalysis Genes Reduces Excess Lipid In Liverapplication
- Atherosclerotic Plaque Reduction Treatments And Compositionsapplication
- Hepatocellular Carcinoma Treatments, Prophylactic Therapies And Compositions For Use Therewithapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.